Valeant Pharmaceuticals has proposed a merger with Allergan.
ThromboGenics’ ocriplasmin (Jetrea) as been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT).
Alcon Laboratories opened the doors this week to its new state-of-the-art ophthalmic pharmaceutical manufacturing facility in the Tuas Biomedical Park in Singapore.
One intravitreal injection of QPI-1007 (Quark Pharmaceuticals) to treat nonarteritic anterior ischemic optic neuropathy (NAION) was safe with no serious adverse events in a phase I trial, and most patients gained 3 or more lines of vision, according to Bradley Katz, MD, PhD, who reported the results on behalf of the Quark Study Group.
ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.